Clinical Policy Title: Bronchial thermoplasty for severe asthma
|
|
- Willis Grant
- 6 years ago
- Views:
Transcription
1 Clinical Policy Title: Bronchial thermoplasty for severe asthma Clinical Policy Number: Effective Date: March 1, 2013 Initial Review Date: October 16, 2013 Most Recent Review Date: October 19, 2016 Next Review Date: October 2017 Policy contains: Bronchial thermoplasty (BT) for severe asthma. Related policies: None. ABOUT THIS POLICY: AmeriHealth Caritas Iowa has developed clinical policies to assist with making coverage determinations. AmeriHealth Caritas Iowa s clinical policies are based on guidelines from established industry sources, such as the Centers for Medicare & Medicaid Services (CMS), state regulatory agencies, the American Medical Association (AMA), medical specialty professional societies, and peer-reviewed professional literature. These clinical policies along with other sources, such as plan benefits and state and federal laws and regulatory requirements, including any state- or plan-specific definition of medically necessary, and the specific facts of the particular situation are considered by AmeriHealth Caritas Iowa when making coverage determinations. In the event of conflict between this clinical policy and plan benefits and/or state or federal laws and/or regulatory requirements, the plan benefits and/or state and federal laws and/or regulatory requirements shall control. AmeriHealth Caritas Iowa s clinical policies are for informational purposes only and not intended as medical advice or to direct treatment. Physicians and other health care providers are solely responsible for the treatment decisions for their patients. AmeriHealth Caritas Iowa s clinical policies are reflective of evidence-based medicine at the time of review. As medical science evolves, AmeriHealth Caritas Iowa will update its clinical policies as necessary. AmeriHealth Caritas Iowa s clinical policies are not guarantees of payment Coverage policy AmeriHealth Caritas Iowa considers the use of bronchial thermoplasty (BT) for the treatment of severe or non-severe asthma to be investigational and, therefore, not medically necessary. Limitations: All other uses of BT for the treatment of severe or non-severe asthma are not medically necessary. Alternative covered services: According to the National Asthma Education and Prevention Program (NAEPP) Expert Panel Report, Guidelines for the Diagnosis and Management of Asthma : The first line of treatment for patients with severe persistent asthma is inhaled corticosteroids (ICS) and long-acting beta agonists (LABA). 1
2 If the patient does not achieve control on medium doses of corticosteroids, higher doses of ICS and LABA are used, as prescribed by treating provider. There is no clear established alternative to BT. Background Asthma is a common chronic airway disorder characterized by periods of reversible airflow obstruction, known as asthma attacks. Airflow is obstructed by inflammation and airway hyper-reactivity (contraction of the small muscles surrounding the airways) in reaction to certain exposures. Exposures include exercise; infection; allergens (e.g., pollen); occupational exposures (e.g., chemicals); and airborne irritants (e.g., environmental tobacco smoke). Symptoms may include wheezing, coughing, shortness of breath, and chest tightness. It is not clear how to prevent asthma from developing and there is no cure. Yet the means to control and prevent exacerbations in persons who have asthma are well established in evidence-based clinical guidelines. In 2010, an estimated 25.7 million Americans had asthma 18.7 million adults ages 18 and over, and 7.0 million children, ages 0 17 years. In the last decade, the proportion of people with asthma in the United States grew by nearly 15 percent. In 2009, asthma caused: Hospitalizations: 479,300. Emergency room visits: 1.9 million. Doctor s visits: 8.9 million. Current guidelines emphasize that asthma therapy be selected on the basis of disease severity. For intermittent asthma, no daily medication is advised for the majority of patients. To relieve occasional symptoms, a rapid-acting, inhaled β2-agonist is prescribed. Patients with mild, persistent asthma require controller medication with a daily inhaled glucocorticoid, to achieve and maintain asthma control. Other treatment options include sustained-release theophylline, chromones, or a leukotriene modifier. For moderate persistent asthma, the preferred therapy is a combination of an inhaled glucocorticoid and a long-acting, inhaled β2-agonist. Sustained-release theophylline or a leukotriene modifier can be used instead of the β2-agonist. Primary therapy for severe, persistent asthma includes an inhaled glucocorticoid at higher doses, in addition to a long-acting, inhaled β2-agonist. Some patients with severe asthma do not achieve acceptable control despite maximal medical therapy. BT is intended for the treatment of severe, persistent asthma not well controlled by long-acting bronchodilators or glucocorticoids, in patients ages 18 years and older. BT is designed to weaken and partially destroy the smooth muscle that constricts the airways during asthma attacks. The procedure relies on a catheter that has an expandable array of electrodes and a fiber optic camera, which allows the physician to see inside the lung. After the catheter is threaded into the airway, a wire leading out of the back end of the catheter is attached to a radiofrequency generator, and a lever is operated that causes the electrodes to curl into a ball shape around the front end of the catheter. The 1
3 curved electrodes are held against the bronchial walls and an electrical current is applied to generate heat that destroys the smooth muscle underneath the lining of the bronchial passages. The complete thermoplasty procedure is performed in three treatment sessions targeting different segments of the lung, with a recovery period of 3 weeks between each session. BT is typically performed by a pulmonologist, with the patient under moderate sedation or general anesthesia. The use of BT was evaluated in three randomized controlled trials (RCTs) supported by the manufacturer of the Alair Bronchial Thermoplasty System (Boston Scientific Corporation, Natick, MA/Asthmatx Inc., Sunnyvale, California.) (See the clinical trial section.) Searches AmeriHealth Caritas Iowa searched PubMed and the databases of: UK National Health Services Centre for Reviews and Dissemination. Agency for Healthcare Research and Quality s National Guideline Clearinghouse and other evidence-based practice centers. The Centers for Medicare & Medicaid Services (CMS). We conducted searches on September 16, Search terms were asthma and BT. We included: Findings Systematic reviews, which pool results from multiple studies to achieve larger sample sizes and greater precision of effect estimation than in smaller primary studies. Systematic reviews use predetermined transparent methods to minimize bias, effectively treating the review as a scientific endeavor, and are thus rated highest in evidence-grading hierarchies. Guidelines based on systematic reviews. Economic analyses, such as cost-effectiveness, and benefit or utility studies (but not simple cost studies), reporting both costs and outcomes sometimes referred to as efficiency studies which also rank near the top of evidence hierarchies. The three available RCTs that evaluated BT for the treatment of asthma provide evidence that, in the short term, bronchial therapy appears reasonably safe and somewhat effective for patients who have severe asthma. Treatment with thermoplasty was associated with statistically significant increases in complications, including dyspnea, wheezing, chest discomfort, night awakenings, sputum discoloration, cough, and productive cough during the treatment period, but most of these complications were mild or moderate in severity. During the first year after thermoplasty, benefits including improved quality of life, symptom relief, reduced medication use, and reductions in emergency room visits were observed; however, the benefits varied somewhat in the three RCTs. 2
4 These differences in benefits may have resulted from differences in study protocols, because the two smaller RCTs involved partial discontinuation of certain asthma medications. Although observation of benefits of thermoplasty after medication reduction may give a more accurate representation of the clinical situation and a desire to minimize medication usage and associated side effects of medications, reduction of medication for the control group may have exaggerated symptoms and lead to an overestimation of the benefits of thermoplasty. Only one of the RCTs reported results of controlled follow-up for longer than one year. This study found that, at three years follow-up, the only statistically significant benefit of thermoplasty was an improvement in airway responsiveness. However, this follow-up may have been flawed, since it involved only 69 patients and the drop-out rate was much higher for the control group than for the thermoplasty group. The apparent loss of thermoplasty benefit during longer follow-up may indicate loss of effectiveness over time, or may be a result of control group patients selective dropping out, who have the least well-controlled asthma. Additional controlled studies are needed to assess the long-term safety and efficacy of BT for the treatment of asthma. Summary of clinical evidence: Citation Pavord (2013) Content, Methods, Recommendations 14 patients with severe asthma, ages 18 65, uncontrolled symptoms. Five-year follow-up, comparing each year versus year before BT initiated. Annual respiratory adverse events years 2 5 = 1.4, 2.4, 1.7, 2.4. Reduction in hospitalizations and emergency room visits. Weichsler (2013) 162 given BT for five years. Compared to the year before therapy, 44% reduction in exacerbations, 78% reduction in emergency room visits. Respiratory adverse events and respiratory-related hospital admissions did not change from the first year to the second fifth years. National Institute for Health and Clinical Excellence (NICE) 2012 For patients with severe asthma, BT has been shown to provide some improvements in symptoms and quality of life, as well as reductions in exacerbations and hospital admissions. Although evidence of safety is adequate in the short and medium term, more evidence of long-term safety is needed; therefore, thermoplasty should only be used after establishment of special arrangements for clinical governance, including patient consent and research or audit. The NICE encourages additional research to evaluate the long-term safety and efficacy of thermoplasty (NICE)
5 British Thoracic Society (BTS) 2012 California Technology Assessment Forum (CTAF) (2012) Global Initiative for Asthma (GINA) (2012) Thomson (2011) For patients who have moderate to severe asthma, BT has been associated with a short-term increase in symptoms related to asthma. This procedure reduces symptoms, beginning approximately six weeks after the final thermoplasty treatment. Specific benefits of this procedure are fewer asthma exacerbations, improvements in quality of life, and fewer days lost from work or school due to asthma. The BTS recommends thermoplasty as a potential treatment option in carefully selected patients who have severe, persistent asthma and who are on maximal therapy. Despite this recommendation, the BTS cautions that long-term safety and efficacy of thermoplasty are unclear, so the clinical role of thermoplasty in asthma remains to be established, and this treatment should only be performed at a limited set of specialty centers. The BTS also recommends longer-term follow-up of patients who undergo thermoplasty (BTS 2012). Although the benefits of treatment were limited, net improvements were sufficient to recommend this procedure in patients who have few other options. A particular concern of the CTAF is the potential long-term sequelae of thermoplasty, since few patients have undergone at least five years of follow-up after this procedure (CTAF 2012). This treatment exacerbates asthma during the months following treatment, but results in a subsequent decrease in exacerbations without significantly affecting lung function or asthma symptoms. The long-term safety and efficacy of thermoplasty are not known and GINA recommends caution be used in the selection of patients for this procedure (GINA 2011). 45 treated and 24 control subjects. Respiratory adverse events of the second fifth years were 1.2, 1.3, 1.2, and 1.1. No increase in hospital admissions or emergency visits in the second fifth years. Glossary Alair Bronchial Thermoplasty System (Asthmatx Inc.) The Alair Bronchial Thermoplasty System treats severe persistent asthma by delivering thermal radiofrequency energy to the airway wall, which heats the tissue in a controlled manner and reduces airway smooth muscle mass (muscle thickness). Patients are treated in multiple sessions that target different areas of the lungs. 4
6 Asthma A chronic disorder of the airways, characterized by episodes of impaired breathing. Asthma is caused by airflow obstruction, due to bronchial hyper-responsiveness and underlying inflammation. Bronchial thermoplasty (BT) A bronchoscopic procedure that uses radiofrequency ablation to reduce the mass of airway smooth muscle (ASM), thus attenuating bronchoconstriction. Extrinsic asthma Asthma caused by some factor in the environment, usually atopic in nature. Status asthmaticus A particularly severe asthmatic attack that does not respond adequately to usual therapy and may require hospitalization. References Professional society guidelines/other: American Lung Association (ALA). Trends in Asthma Morbidity and Mortality. September Accessed September 15, British Thoracic Society (BTS). British Thoracic Society Guideline for Advanced Diagnostic and Therapeutic Flexible Bronchoscopy in Adults. January 4, Accessed September 15, Boston Scientific website. Bronchial Thermoplasty for asthma. Med Lett Drugs Ther. August 23, 2010; 52(1345): Accessed September 15, Centers for Disease Control and Prevention s (CDC) National Center for Health Statistics, Office of Analysis and Epidemiology. Lara J. Akinbami and Xiang Liu. CDC s National Center for Environmental Health and the National Asthma Control Program, Jeanne E. Moorman, Cathy Bailey, Hatice S. Zahran, Michael King, and Carol A. Johnson. Expert Panel Report 3 (EPR-3): Guidelines for the Diagnosis and Management of Asthma-Summary Report The Journal of allergy and clinical immunology. Nov 2007; 120(5 Suppl): S Global Initiative for Asthma (GINA).Global Strategy for Asthma Management and Prevention. Updated Accessed September 15, Hayes Inc. Directory, Alair Bronchial Thermoplasty System for Treatment of Asthma. December 28,
7 National Heart, Lung, and Blood Institute, National Institutes of Health. National Asthma Education and Prevention Program. Expert Panel Report 3: Guidelines for the diagnosis and management of asthma. NIH Publication No National Institute for Health and Clinical Excellence (NICE). Bronchial Thermoplasty for severe asthma London, UK: National Institute for Health and Clinical Excellence; NICE Interventional Procedure Guidance No Accessed September 15, Peer-reviewed references: Bateman ED, Hurd SS, Barnes PJ, et al. Global strategy for asthma management and prevention: GINA executive summary. Eur Respir J. 2008; 31(1): Castro M, Rubin AS, Laviolette M, et al. Effectiveness and safety of Bronchial Thermoplasty in the treatment of severe asthma: a multicenter, randomized, double-blind, sham-controlled clinical trial. Am. J. Respir. Crit. Care Med. Jan ; 181(2): Castro M, Rubin AS, Laviolette M, et al.; AIR2 Trial Study Group. Effectiveness and safety of Bronchial Thermoplasty in the treatment of severe asthma: a multicenter randomized, double-blind, shamcontrolled clinical trial. Am J Respir Crit Care Med Jan 15; 181(2): Castro M, Rubin A, Laviolette M, et al.; AIR2 Trial Study Group. Persistence of effectiveness Bronchial Thermoplasty in patients with severe asthma. Ann Allergy Asthma Immunol Jul; 107(1): Cox G, Thomson NC, Rubin AS, et al.; AIR Trial Study Group. Asthma control during the year after Bronchial Thermoplasty. N Engl J Med Mar 29; 356(13): Cox G, Miller JD, McWilliams A, et al. Bronchial Thermoplasty for asthma. Am J Respir Crit Care Med May 1; 173(9): Cox G. Bronchial Thermoplasty for severe asthma. Curr. Opin. Pulm. Med. Jan 2011; 17(1): Pavord ID, Cox G, Thomson NC, et al. Safety and efficacy of Bronchial Thermoplasty in symptomatic, severe asthma. Am. J. Respir. Crit. Care Med. Dec ; 176(12): Pavord ID, Thomson NC, Niven RM, et al. Safety of bronchial thermoplasty in patients with severe refractory asthma. Ann Allergy Asthma Immunol. 2013; 111(5): Tice JA. Bronchial Thermoplasty for the treatment of severe asthma. Technology Assessment. San Francisco, CA: California Technology Assessment Forum (CTAF); October 19,
8 Thomson NC, Rubin AS, Niven RM, et al. Long-term (5 year) safety of bronchial thermoplasty: Asthma Intervention Research (AIR) trial. BMC Pulm Med. 2011; 11:8. Weichsler ME, Laviolette M, Rubin AS, et al. Bronchial thermoplasty: Long-term safety and effectiveness in patients with severe persistent asthma. J Allergy Clin Immunol 2013; 132(6): Clinical trials: Searched clinicaltrials.gov on September 15, 2016, using the term bronchial thermoplasty Open Studies. Nine studies found, two relevant: University of Alabama at Birmingham, Birmingham, Alabama, United States. A Prospective Observational Study of Biopredictors of Bronchial Thermoplasty Response in Patients with Severe Refractory Asthma (BTR Study). Published June 21, Updated December &rank=6 Oklahoma City, Oklahoma, United States. Spirometric Response to Bronchial Thermoplasty in Patients With Severe Asthma Published May 5, Updated May CMS National Coverage Determinations (NCDs): No NCDs identified as of the writing of this policy. Local Coverage Determinations (LCDs): No LCDs identified as of the writing of this policy. Commonly submitted codes Below are the most commonly submitted codes for the service(s)/item(s) subject to this policy. This is not an exhaustive list of codes. Providers are expected to consult the appropriate coding manuals and bill accordingly. CPT Code Description Comments Bronchoscopy, rigid or flexible, including fluoroscopic guidance, when performed; with bronchial Thermoplasty, one lobe Bronchoscopy, rigid or flexible, including fluoroscopic guidance, when performed; with bronchial thermoplasty, two or more lobes. ICD-10 Code Description Comment J44.0 Chronic obstructive pulmonary disease with acute lower respiratory 7
9 Infection J44.1 Chronic obstructive pulmonary disease with (acute) exacerbation J44.9 Chronic obstructive pulmonary disease, unspecified J45.20 Mild intermittent asthma, uncomplicated J45.21 Mild intermittent asthma with (acute) exacerbation J45.22 Mild intermittent asthma with status asthmaticus J45.30 Mild persistent asthma, uncomplicated J45.31 Mild persistent asthma with (acute) exacerbation J45.32 Mild persistent asthma with status asthmaticus J45.40 Moderate persistent asthma, uncomplicated J45.41 Moderate persistent asthma with (acute) exacerbation J44.42 Moderate persistent asthma with status asthmaticus J45.50 Severe persistent asthma, uncomplicated J45.51 Severe persistent asthma with (acute) exacerbation J45.52 Severe persistent asthma with status asthmaticus J Unspecified asthma with (acute) exacerbation J Unspecified asthma with status asthmaticus J Unspecified asthma, uncomplicated J Exercise induced bronchospasm J Cough variant asthma J Other asthma HCPCS Level II N/A Description Comment 8
Clinical Policy Title: Bronchial thermoplasty for severe asthma
Clinical Policy Title: Bronchial thermoplasty for severe asthma Clinical Policy Number: CCP.1058 Effective Date: March 1, 2013 Initial Review Date: October 16, 2013 Most Recent Review Date: October 2,
More informationSubject: Bronchial Thermoplasty
Subject: Bronchial Thermoplasty Guidance Number: MCG-171 Revision Date(s): Original Effective Date: 6/12/14 Medical Coverage Guidance Approval Date: 6/12/14 PREFACE This Medical Guidance is intended to
More informationCorporate Medical Policy
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: bronchial_thermoplasty 10/2010 3/2018 3/2019 3/2018 Description of Procedure or Service Bronchial thermoplasty
More informationHCT Medical Policy. Bronchial Thermoplasty. Policy # HCT113 Current Effective Date: 05/24/2016. Policy Statement. Overview
HCT Medical Policy Bronchial Thermoplasty Policy # HCT113 Current Effective Date: 05/24/2016 Medical Policies are developed by HealthyCT to assist in administering plan benefits and constitute neither
More informationBRONCHIAL THERMOPLASTY
BRONCHIAL THERMOPLASTY UnitedHealthcare Community Plan Medical Policy Policy Number: CS014.E Effective Date: July 1, 2017 Table of Contents Page INSTRUCTIONS FOR USE... 1 BENEFIT CONSIDERATIONS... 1 COVERAGE
More informationBRONCHIAL THERMOPLASTY
Review Article 155 BRONCHIAL THERMOPLASTY Prince James* and Richa Gupta* (Received on 4.5.2010; Accepted after revision on 5.9.2011) Summary: Even with the use of maximum pharmacological treatment, asthma
More informationBronchial Thermoplasty
Bronchial Thermoplasty Policy Number: 7.01.127 Last Review: 9/2014 Origination: 11/2010 Next Review: 3/2015 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will not provide coverage for bronchial
More informationBRONCHIAL THERMOPLASTY
BRONCHIAL THERMOPLASTY UnitedHealthcare Oxford Clinical Policy Policy Number: RESPIRATORY 009.11 T2 Effective Date: August 1, 2017 Table of Contents Page BRONCHIAL THERMOPLASTY... 1 INSTRUCTIONS FOR USE...
More informationBRONCHIAL THERMOPLASTY
BRONCHIAL THERMOPLASTY UnitedHealthcare of California (HMO) UnitedHealthcare Benefits Plan of California (IEX EPO, IEX PPO) UnitedHealthcare of Oklahoma, Inc. UnitedHealthcare of Oregon, Inc. UnitedHealthcare
More informationRobert Kruklitis, MD, PhD Chief, Pulmonary Medicine Lehigh Valley Health Network
Robert Kruklitis, MD, PhD Chief, Pulmonary Medicine Lehigh Valley Health Network Robert.kruklitis@lvh.com Correlation of a Asthma pathophyisology with basic science Asthma (Physiology) Bronchodilators
More informationBronchial Thermoplasty For Severe Persistent Asthma
Bronchial Thermoplasty For Severe Persistent Asthma Faisal Khan MD Center For Respiratory and Sleep Medicine Indiana Internal Medicine Consultants Franciscan Saint Francis hospital Agenda Burden of Severe
More informationEndobronchial Thermoplasty
Endobronchial Thermoplasty Asthma Education Day Thursday, October 30, 2014 Cynthia Ray, MD, FCCP Senior Staff Physician Interventional Pulmonology Pulmonary and Critical Care Medicine Henry Ford Hospital
More informationMedical Review Criteria Bronchial Thermoplasty
Medical Review Criteria Bronchial Thermoplasty Subject: Bronchial Thermoplasty Background: Bronchial thermoplasty is proposed as a treatment option for adults whose severe persistent asthma is not well
More informationEndobronchial Thermoplasty
Endobronchial Thermoplasty Michigan Society for Respiratory Care Monday, October 5, 2015 Cynthia Ray, MD, FCCP Senior Staff Physician Interventional Pulmonology Pulmonary and Critical Care Medicine Henry
More informationBronchial Thermoplasty
Bronchial Thermoplasty Policy Number: 7.01.127 Last Review: 4/2018 Origination: 11/2010 Next Review: 9/2018 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will not provide coverage for bronchial
More informationBronchial Thermoplasty
Medical Policy Manual Surgery, Policy No. 178 Bronchial Thermoplasty Next Review: September 2018 Last Review: October 2017 Effective: November 1, 2017 IMPORTANT REMINDER Medical Policies are developed
More informationClinical Policy Title: Genicular nerve block
Clinical Policy Title: Genicular nerve block Clinical Policy Number: 14.01.10 Effective Date: October 1, 2017 Initial Review Date: September 21, 2017 Most Recent Review Date: October 19, 2017 Next Review
More informationBronchial Thermoplasty
Bronchial Thermoplasty Policy Number: 7.01.127 Last Review: 9/2018 Origination: 11/2010 Next Review: 3/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will not provide coverage for bronchial
More informationWest of Scotland Difficult Asthma Group Statement of Practice
West of Scotland Difficult Asthma Group Statement of Practice Member Health Boards: Ayrshire and Arran Dumfries and Galloway Forth Valley Lanarkshire Glasgow INFORMATION ON THE USE OF BRONCHIAL THERMOPLASTY
More informationClinical Policy Title: Strep testing
Clinical Policy Title: Strep testing Clinical Policy Number: 07.01.09 Effective Date: December 1, 2017 Initial Review Date: October 19, 2017 Most Recent Review Date: November 16, 2017 Next Review Date:
More informationComplements asthma therapy NOT a CURE for Severe. Non pharmacologic treatment of asthma. limits the ability of the airways to constrict.
Bronchial Thermoplasty Karla Provost Pulmonary and Critical Care Medicine 2015 What is Bronchial Thermoplasty Non pharmacologic treatment of asthma Outpatient procedure performed over 3 treatment sessions
More informationWhat is Severe Persistent Asthma? What is Bronchial Thermoplasty Non pharmacologic treatment of asthma
Objectives BT defined What is Severe Persistent Asthma Case Study introduction How is BT performed Pre-op, PACU and Discharge care Who does it work for the criteria for BT Brief overview of BT results
More informationBRONCHIAL THERMOPLASTY
BRONCHIAL THERMOPLASTY UnitedHealthcare Commercial Medical Policy Policy Number: 2018T0542L Effective Date: July 1, 2018 Table of Contents Page INSTRUCTIONS FOR USE... 1 BENEFIT CONSIDERATIONS... 1 COVERAGE
More informationClinical Policy Title: Zoster (shingles) vaccine
Clinical Policy Title: Zoster (shingles) vaccine Clinical Policy Number: 18.02.10 Effective Date: June 1, 2018 Initial Review Date: April 10, 2018 Most Recent Review Date: May 1, 2018 Next Review Date:
More informationRunning Head: THE PRACTICALITY OF BRONCHIAL THERMOPLASTY 1. Review of a New Treatment for Severe Asthma: The Practicality of Bronchial Thermoplasty
Running Head: THE PRACTICALITY OF BRONCHIAL THERMOPLASTY 1 Review of a New Treatment for Severe Asthma: The Practicality of Bronchial Thermoplasty Jessica Orpen Northeastern University THE PRACTICALITY
More informationClinical Policy Title: Cardiac rehabilitation
Clinical Policy Title: Cardiac rehabilitation Clinical Policy Number: 04.02.02 Effective Date: September 1, 2013 Initial Review Date: February 19, 2013 Most Recent Review Date: February 6, 2018 Next Review
More informationClinical Policy Title: Genetic testing for G1691A polymorphism factor V Leiden
Clinical Policy Title: Genetic testing for G1691A polymorphism factor V Leiden Clinical Policy Number: 05.01.03 Effective Date: January 1, 2016 Initial Review Date: July 15, 2015 Most Recent Review Date:
More informationClinical Policy Title: Genetic testing for G1691A polymorphism factor V Leiden
Clinical Policy Title: Genetic testing for G1691A polymorphism factor V Leiden Clinical Policy Number: 05.01.03 Effective Date: January 1, 2016 Initial Review Date: July 15, 2015 Most Recent Review Date:
More informationThe New Medtech Economic Reality MassMEDIC Annual Meeting
The New Medtech Economic Reality MassMEDIC Annual Meeting Susan Posner Vice President sposner@healthadvances.com May 1, 2012 The New Medtech Reality The economic downturn coupled with the focus on health
More informationSmooth Muscle & Asthma: Bronchial Thermoplasty - A Smooth Muscle Modifier
Smooth Muscle & Asthma: Bronchial Thermoplasty - A Smooth Muscle Modifier Mario Castro, MD, MPH Professor of Medicine and Pediatrics Director, The Asthma and Airway Translational Research Unit, Washington
More informationClinical Policy Title: Ketamine for treatment-resistant depression
Clinical Policy Title: Ketamine for treatment-resistant depression Clinical Policy Number: 00.02.13 Effective Date: January 1, 2016 Initial Review Date: August 19, 2015 Most Recent Review Date: January
More informationRESPIRATORY CARE IN GENERAL PRACTICE
RESPIRATORY CARE IN GENERAL PRACTICE Definitions of Asthma and COPD Asthma is due to inflammation of the air passages in the lungs and affects the sensitivity of the nerve endings in the airways so they
More informationClinical Policy Title: Room humidifiers
Clinical Policy Title: Room humidifiers Clinical Policy Number: 17.02.05 Effective Date: February 1, 2017 Initial Review Date: November 16, 2016 Most Recent Review Date: November 16, 2016 Next Review Date:
More informationClinical Policy Title: Abdominal aortic aneurysm screening
Clinical Policy Title: Abdominal aortic aneurysm screening Clinical Policy Number: 08.01.10 Effective Date: August 1, 2017 Initial Review Date: June 22, 2017 Most Recent Review Date: July 20, 2017 Next
More informationClinical Policy Title: Measurement of serum antibodies to infliximab and adalimumab
Clinical Policy Title: Measurement of serum antibodies to infliximab and adalimumab Clinical Policy Number: 01.01.03 Effective Date: January 1, 2016 Initial Review Date: September 16, 2015 Most Recent
More informationBronchial Thermoplasty for the Treatment of Severe Asthma
TITLE: Bronchial Thermoplasty for the Treatment of Severe Asthma AUTHOR: Jeffrey A. Tice, MD Assistant Professor of Medicine Division of General Internal Medicine Department of Medicine University of California
More informationCase-Compare Impact Report
Case-Compare Impact Report October 8, 20 For CME Activity: Developed through an independent educational grant from Genentech: Moderate to Severe Persistent Asthma: A Case-Based Panel Discussion (March
More informationTHE PROMISE OF NEW AND NOVEL DRUGS. Pyng Lee Respiratory & Critical Care Medicine National University Hospital
THE PROMISE OF NEW AND NOVEL DRUGS Pyng Lee Respiratory & Critical Care Medicine National University Hospital Pyng_lee@nuhs.edu.sg Asthma Prevalence, Morbidity, Mortality 235 million suffer from asthma
More informationClinical Policy Title: Breast cancer index genetic testing
Clinical Policy Title: Breast cancer index genetic testing Clinical Policy Number: 02.01.22 Effective Date: January 1, 2017 Initial Review Date: October 19, 2016 Most Recent Review Date: October 19, 2016
More informationClinical Policy Title: Fluorescence in situ hybridization for cervical cancer screening
Clinical Policy Title: Fluorescence in situ hybridization for cervical cancer screening Clinical Policy Number: 01.01.02 Effective Date: April 1, 2015 Initial Review Date: January 21, 2015 Most Recent
More informationLCD for Omalizumab (Xolair ) (L29240)
LCD for Omalizumab (Xolair ) (L29240) Contractor Information Contractor Name First Coast Service Options, Inc. Contractor Number 09102 Contractor Type MAC - Part B LCD ID Number L29240 LCD Information
More informationClinical Policy: Fractional Exhaled Nitric Oxide Reference Number: CP.MP.103
Clinical Policy: Reference Number: CP.MP.103 Effective Date: 01/16 Last Review Date: 01/17 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory and
More informationEndobronchial thermoplasty for asthma
Review Article on Aerodigestive Endoscopy Endobronchial thermoplasty for asthma Felix Zamora 1, Roy Cho 1, Madhuri Rao 2, Heidi Gibson 3, H. Erhan Dincer 1 1 Division of Pulmonary, Allergy, Critical Care
More informationUsefulness of Bronchial Thermoplasty for Patients with a Deteriorating Lung Function
doi: 10.2169/internalmedicine.8965-17 http://internmed.jp CASE REPORT Usefulness of Bronchial Thermoplasty for Patients with a Deteriorating Lung Function Daisuke Minami, Chihiro Ando, Takamasa Nakasuka,
More informationCorporate Medical Policy
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: xolair_omalizumab 9/2003 11/2017 11/2018 11/2017 Description of Procedure or Service Asthma is a chronic
More information10801 Sixth St, Rancho Cucamonga, CA Tel (909) Fax (909) Visit our web site at:
for the Diagnosis and Management of Asthma and Other Pulmonary Disorders IEHP Policy: Based on a review of the currently available literature, there is insufficient evidence to support the use of FE NO
More informationDiagnosis, Treatment and Management of Asthma
Diagnosis, Treatment and Management of Asthma Asthma is a complex disorder characterized by variable and recurring symptoms, airflow obstruction, bronchial hyperresponsiveness, and an underlying inflammation.
More informationClinical Policy Title: Abdominal aortic aneurysm screening
Clinical Policy Title: Abdominal aortic aneurysm screening Clinical Policy Number: 08.01.10 Effective Date: August 1, 2017 Initial Review Date: June 22, 2017 Most Recent Review Date: June 5, 2018 Next
More informationAsthma Management for the Athlete
Asthma Management for the Athlete Khanh Lai, MD Assistant Professor Division of Pediatric Pulmonary and Sleep Medicine University of Utah School of Medicine 2 nd Annual Sports Medicine Symposium: The Pediatric
More informationClinical Policy Title: Abdominal aortic aneurysm screening
Clinical Policy Title: Abdominal aortic aneurysm screening Clinical Policy Number: 08.01.10 Effective Date: August 1, 2017 Initial Review Date: June 22, 2017 Most Recent Review Date: June 5, 2018 Next
More informationAir Flow Limitation. In most serious respiratory disease, a key feature causing morbidity and functional disruption is air flow imitation.
Asthma Air Flow Limitation In most serious respiratory disease, a key feature causing morbidity and functional disruption is air flow imitation. True whether reversible, asthma and exercise-induced bronchospasm,
More informationNG80. Asthma: diagnosis, monitoring and chronic asthma management (NG80)
Asthma: diagnosis, monitoring and chronic asthma management (NG80) NG80 NICE has checked the use of its content in this product and the sponsor has had no influence on the content of this booklet. NICE
More informationConnecting Health & Housing: Asthma and the Home. Presented by: The California-Nevada Public Health Training Center
Connecting Health & Housing: Asthma and the Home Presented by: The California-Nevada Public Health Training Center Funded by Grant #UB6HP20202 from the Health Resources and Services Administration, U.S.
More informationAsthma in Pediatric Patients. DanThuy Dao, D.O., FAAP. Disclosures. None
Asthma in Pediatric Patients DanThuy Dao, D.O., FAAP Disclosures None Objectives 1. Discuss the evaluation and management of asthma in a pediatric patient 2. Accurately assess asthma severity and level
More informationClinical Policy Title: Exhaled nitric oxide for diagnosis of lung disease
Clinical Policy Title: Exhaled nitric oxide for diagnosis of lung disease Clinical Policy Number: 07.01.04 Effective Date: June 1, 2014 Initial Review Date: February 19, 2014 Most Recent Review Date: November
More informationDISCLOSURE. Dr. Plummer has declared no conflicts of interest related to the content of his presentation.
DISCLOSURE Dr. Plummer has declared no conflicts of interest related to the content of his presentation. New Codes for 2013 NAMDRC Annual Meeting March 23, 2013 Alan L. Plummer, MD Professor of Medicine
More informationPOLICIES AND PROCEDURE MANUAL
POLICIES AND PROCEDURE MANUAL Policy: MP230 Section: Medical Benefit Policy Subject: Outpatient Pulmonary Rehabilitation I. Policy: Outpatient Pulmonary Rehabilitation II. Purpose/Objective: To provide
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Xolair (omalizumab) Page 1 of 15 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Xolair (omalizumab) Prime Therapeutics will review Prior Authorization requests.
More informationClinical Policy Title: Pharmacogenomic tests for psychiatric medications
Clinical Policy Title: Pharmacogenomic tests for psychiatric medications Clinical Policy Number: 02.02.01 Effective Date: October 1, 2015 Initial Review Date: April 15, 2015 Most Recent Review Date: May
More informationClinical Policy Title: Discography
Clinical Policy Title: Discography Clinical Policy Number: 03.01.01 Effective Date: January 1, 2017 Initial Review Date: October 19, 2016 Most Recent Review Date: October 19, 2017 Next Review Date: October
More informationPharmacy Medical Policy IgE Receptor Binding Inhibitors
Pharmacy Medical Policy IgE Receptor Binding Inhibitors Table of Contents Policy: Commercial Policy History Endnotes Policy: Medicare Information Pertaining to All Policies Forms Coding Information References
More informationASTHMA IN THE PEDIATRIC POPULATION
ASTHMA IN THE PEDIATRIC POPULATION SEARCH Rotation 2 August 23, 2010 Objectives Define asthma as a chronic disease Discuss the morbidity of asthma in pediatrics Discuss a few things that a health center
More informationDATE: 09 December 2009 CONTEXT AND POLICY ISSUES:
TITLE: Tiotropium Compared with Ipratropium for Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease: A Review of the Clinical Effectiveness DATE: 09 December 2009 CONTEXT AND POLICY
More informationXolair (Omalizumab) Drug Prior Authorization Protocol (Medical Benefit & Part B Benefit)
Line of Business: All Lines of Business Effective Date: August 16, 2017 Xolair (Omalizumab) Drug Prior Authorization Protocol (Medical Benefit & Part B Benefit) This policy has been developed through review
More informationClinical Policy Title: Exhaled nitric oxide for diagnosis of lung disease
Clinical Policy Title: Exhaled nitric oxide for diagnosis of lung disease Clinical Policy Number: 07.01.04 Effective Date: June 1, 2014 Initial Review Date: February 19, 2014 Most Recent Review Date: November
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE
DRAFT NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE 1 Guideline title SCOPE Chronic obstructive pulmonary disease: the management of adults with chronic obstructive pulmonary disease in primary
More informationHealthPartners Care Coordination Clinical Care Planning and Resource Guide ASTHMA
The following evidence based guideline was used in developing this clinical care guide: National Institute of Health (NIH National Heart, Lung, and Blood Institute (NHLBI) and American Academy of Allergy,
More informationClinical Policy Title: Altered auditory feedback devices for speech dysfluency (stuttering)
Clinical Policy Title: Altered auditory feedback devices for speech dysfluency (stuttering) Clinical Policy Number: 17.02.02 Effective Date: January 1, 2016 Initial Review Date: August 19, 2015 Most Recent
More informationClinical Policy Title: Seasonal influenza testing
Clinical Policy Title: Seasonal influenza testing Clinical Policy Number: 07.01.08 Effective Date: October 1, 2017 Initial Review Date: August 17, 2017 Most Recent Review Date: September 21, 2017 Next
More informationClinical Policy Title: Ear tubes (tympanostomy)
Clinical Policy Title: Ear tubes (tympanostomy) Clinical Policy Number: 11.03.05 Effective Date: January 1, 2015 Initial Review Date: September 17, 2014 Most Recent Review Date: September 21, 2017 Next
More informationLife-long asthma and its relationship to COPD. Stephen T Holgate School of Medicine University of Southampton
Life-long asthma and its relationship to COPD Stephen T Holgate School of Medicine University of Southampton Definitions COPD is a preventable and treatable disease with some significant extrapulmonary
More informationImproving Outcomes in the Management & Treatment of Asthma. April 21, Spring Managed Care Forum
Improving Outcomes in the Management & Treatment of Asthma April 21, 2016 2016 Spring Managed Care Forum David M. Mannino, M.D. Professor Department of Preventive Medicine and Environmental Health University
More informationMANAGING ASTHMA. Nancy Davis, RRT, AE-C
MANAGING ASTHMA Nancy Davis, RRT, AE-C What is asthma? Asthma is a chronic respiratory disease characterized by episodes or attacks of inflammation and narrowing of small airways in response to asthma
More information2017 Blue Cross and Blue Shield of Louisiana
Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided
More informationCigna Medical Coverage Policy
Cigna Medical Coverage Policy Subject Bronchial Thermoplasty Table of Contents Coverage Policy... 1 General Background... 1 Coding/Billing Information... 7 References... 8 Effective Date... 7/15/2014 Next
More informationClinical Policy Title: Computerized gait analysis
Clinical Policy Title: Computerized gait analysis Clinical Policy Number: 15.01.01 Effective Date: October 1, 2014 Initial Review Date: May 21, 2014 Most Recent Review Date: June 22, 2017 Next Review Date:
More informationClinical Policy Title: Immediate post-concussion assessment and cognitive testing (ImPACT)
Clinical Policy Title: Immediate post-concussion assessment and cognitive testing (ImPACT) Clinical Policy Number: 09.01.02 Effective Date: September 1, 2013 Initial Review Date: February 18, 2013 Most
More informationAsthma. Rachel Miller, MD, FAAAAI Director Allergy and Immunology New York Presbyterian Hospital. Figure 1 Asthma Prevalence,
Asthma Rachel Miller, MD, FAAAAI Director Allergy and Immunology New York Presbyterian Hospital Figure 1 Asthma Prevalence, 1980-2000 * Gap between 1995-1996 and 1997 indicates a break in trend due to
More informationSupplementary Medications during asthma attack. Prof. Dr Finn Rasmussen PhD. DrMedSc. Near East University Hospital North Cyprus
Supplementary Medications during asthma attack Prof. Dr Finn Rasmussen PhD. DrMedSc. Near East University Hospital North Cyprus Conflicts of Interest None Definition of Asthma Airway narrowing that is
More informationCombination Beta2-Agonist/Corticosteroid Inhalers Policy Number: Last Review: Origination: Next Review: Policy When Policy Topic is covered:
Combina ation Beta2-Agonist/Corticosteroid Inhalers Policy Number: 5.01.572 Origination: 06/2014 Last Review: 07/2014 Next Review: 07/2015 Policy BCBSKC will provide coverage for the combination beta2-agonist/corticosteroid
More informationMEDICAL POLICY. Proprietary Information of YourCare Health Plan
MEDICAL POLICY PAGE: 1 OF: 6 If the member's subscriber contract excludes coverage for a specific service it is not covered under that contract. In such cases, medical policy criteria are not applied.
More informationIn 2002, it was reported that 72 of 1000
REPORTS Aligning Patient Care and Asthma Treatment Guidelines Eric Cannon, PharmD Abstract This article describes how the National Asthma Education and Prevention Program Guidelines for the Diagnosis and
More informationInternational Journal of Medical Science and Education pissn eissn
COMPARISON OF MONTELUKAST AND KETOTIFEN AS ADD ON THERAPY IN MODERATE AND SEVERE PERSISTENT BRONCHIAL ASTHMA Dr. Gaurav Chhabra 1, Dr. Shubhakaran Sharma 2* Original research article 1,2 Associate professor,
More informationThe methodology behind GINA and EPR-3 medication recommendations: Stepwise treatment in asthma
The methodology behind GINA and EPR-3 medication recommendations: Stepwise treatment in asthma Maureen George PhD RN AE-C FAAN Columbia University mg3656@cumc.columbia.edu Faculty Disclosures Maureen George
More informationProvider Respiratory Inservice
Provider Respiratory Inservice 2 Welcome Opening Remarks We will cover: Definition of Asthma & COPD Evidence based guidelines for diagnosis, evaluation, and management of asthma Evidence based guidelines
More informationand will be denied as not medically necessary** if not met. This criterion only applies to the initial
Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided
More information(Asthma) Diagnosis, monitoring and chronic asthma management
Dubai Standards of Care 2018 (Asthma) Diagnosis, monitoring and chronic asthma management Preface Asthma is one of the most common problem dealt with in daily practice. In Dubai, the management of chronic
More informationOn completion of this chapter you should be able to: discuss the stepwise approach to the pharmacological management of asthma in children
7 Asthma Asthma is a common disease in children and its incidence has been increasing in recent years. Between 10-15% of children have been diagnosed with asthma. It is therefore a condition that pharmacists
More informationSCREENING AND PREVENTION
These protocols are designed to implement standard guidelines, based on the best evidence, that provide a consistent clinical experience for AHC II Integrated Clinical Delivery Network patients and allow
More informationTHE NHLBI GUIDELINES: WHERE DO WE STAND AND WHAT IS THE NEW DIRECTION FROM THE NAEPP?
THE NHLBI GUIDELINES: WHERE DO WE STAND AND WHAT IS THE NEW DIRECTION FROM THE NAEPP? Peter S. Creticos, MD ABSTRACT In 1991 and 1997, the National Heart, Lung, and Blood Institute s National Asthma Education
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE 1 Guideline title SCOPE Chronic obstructive pulmonary disease: the management of adults with chronic obstructive pulmonary disease in primary and secondary
More informationASTHMA CARE FOR CHILDREN BASKET OF CARE SUBCOMMITTEE Report to: Minnesota Department of Health. June 22, 2009
This document is made available electronically by the Minnesota Legislative Reference Library as part of an ongoing digital archiving project. http://www.leg.state.mn.us/lrl/lrl.asp ASTHMA CARE FOR CHILDREN
More informationOutline FEF Reduced FEF25-75 in asthma. What does it mean and what are the clinical implications?
Reduced FEF25-75 in asthma. What does it mean and what are the clinical implications? Fernando Holguin MD MPH Director, Asthma Clinical & Research Program Center for lungs and Breathing University of Colorado
More informationDiagnosis and Management of Asthma in Children based on the British Thoracic Society and Scottish Intercollegiate Guidelines Network September 2016
Diagnosis and Management of Asthma in Children based on the British Thoracic Society and Scottish Intercollegiate Guidelines Network September 2016 Diagnosis: There is no lower limit to the age at which
More informationClinical Policy Title: Fluorescence in situ hybridization for cervical cancer screening
Clinical Policy Title: Fluorescence in situ hybridization for cervical cancer screening Clinical Policy Number: 01.01.02 Effective Date: April 1, 2015 Initial Review Date: January 21, 2015 Most Recent
More informationEmily DiMango, MD Asthma II
Emily DiMango, MD Asthma II Director John Edsall/John Wood Asthma Center Columbia University Medical Center HP 2000 Goal: 2.25/1,000 Comparison of Asthma Hospitalization Rates in Children Aged 0-14 in
More informationNancy Davis, RRT, AE-C
Nancy Davis, RRT, AE-C Asthma Statistics 25.6 million Americans diagnosed with asthma 6.8 million are children 10.5 million missed school days per year 14.2 lost work days for adults Approximately 10%
More information